CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...
Zacks.com on MSN
How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up
TEM sees modest Q3 reimbursement gains, but FDA and ADLT pathways for xT, xF and xR assays could narrow its pricing gap over 2025-2026.
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the company’s PurISTSM algorithmic test has received a ...
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and ...
Precision medicine company Tempus has inked another major pharma collaboration as drug developers integrate artificial intelligence into their R&D pipelines. As part of a multiyear strategic ...
Tempus AI stock is showing a mixed technical picture, with a moderately bearish trend and ongoing selling pressure, indicating potential downside risk. The stock, at $69.85, sits well below its ...
CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...
Tempus AI, Inc. is positioned for growth as U.S. pharmaceutical reshoring and regulatory scrutiny increase demand for data-driven healthcare services. Genomics and Data Services segments are ...
Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; ...
Tempus AI has expanded its relationship with Personalis, investing $36 million in the oncology biotech and becoming the exclusive commercial partner for its test to detect minimal residual disease, or ...
Tempus AI has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a whopping 155% on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback